(Reuters) – People who got Johnson & Johnson Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc/BioNTech SE or Moderna Inc, a study run by the National Institutes of Health…
Read More
Immune modulator drugs for COVID-19 focus of major NIH clinical trial
One of the most vexing aspects of the COVID-19 pandemic is the novel coronavirus’s ability to turn the body’s immune system against the body. After the virus has been cleared from the body, the immune system sometimes continues to hurtle…
Read More
NIH Launches Trial of Antibody Drugs Against COVID-19
WEDNESDAY, Oct. 14, 2020 — A study to assess whether certain approved or experimental drugs are effective against COVID-19 and warrant testing in large clinical trials has been launched by the U.S. National Institutes of Health (NIH). The research will…
Read More
NIH trial to test antibodies and other therapeutics for mild, moderate COVID-19
A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease. Researchers sponsored by the National Institute of Allergy and…
Read More